Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KadimastemXTAE:KDST 21 EBIT per Share is ₪-1.92 as of Dec. 2025. GuruFocus rates XTAE:KDST with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 1,172 Biotechnology companies, Kadimastem ranks better than 76.45% on this metric.
Kadimastem's EBIT per Share for the
six
months ended in Dec. 2025 was ₪-0.92.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-1.92.
During the past 3 years, the average EBIT per Share Growth Rate was 36.40% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 40.30% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 15.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Kadimastem's EBIT per Share or its related term are showing as below:
XTAE:KDST'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49.5 Med: 12.05 Max: 49.2
Current: 36.4
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Kadimastem was 49.20% per year. The lowest was -49.50% per year. And the median was 12.05% per year.
XTAE:KDST's 3-Year EBIT Growth Rate is ranked better than 76.45% of 1172
companies
in the Biotechnology industry
Industry Median: 15.5
vs XTAE:KDST: 36.40
Kadimastem's EBIT for the
six
months ended in Dec. 2025 was ₪-2.73 Mil.
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Kadimastem EBIT per Share Related Terms
Kadimastem EBIT per Share Historical Data
* Premium members only.
The historical data trend for Kadimastem's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-1.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kadimastem (XTAE:KDST) has a EBIT per Share of ₪-1.92 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kadimastem and its competitors. According to the industry distribution chart, Kadimastem ranks #276 out of 1172 companies in the Biotechnology industry, placing it in the top 23.5%.
Is Kadimastem's EBIT per Share too high?
Kadimastem's current EBIT per Share is ₪-1.92. Based on the distribution chart, Kadimastem ranks #276 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kadimastem has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Kadimastem's EBIT per Share compare to MRKR and HOWL?
According to the Biotechnology industry distribution chart, Kadimastem ranks #276 out of 1172 companies for EBIT per Share. This places Kadimastem in the top 24% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kadimastem and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kadimastem's current EBIT per Share is ₪-1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kadimastem stock overvalued right now?
Kadimastem (XTAE:KDST) has a current EBIT per Share of ₪-1.92. The current EBIT per Share is ₪-1.92. Kadimastem's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Kadimastem (XTAE:KDST), the current EBIT per Share is ₪-1.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.
21GF Score
Get the complete analysis for XTAE:KDST
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:KDST has been successfully added to your 
